Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Readnour Robin Shane
Director at AN2 Therapeutics. Filing since 29 Mar 2022.
CIK 0001914883
Company
Date
Role
Action
Shares
Amount
Of holding
ANTX
AN2 Therapeutics, Inc.
9 Sep 2026
Director
Sold on a plan
1,108
$6.67K
0.2%
ANTX
AN2 Therapeutics, Inc.
8 Sep 2026
Director
Sold on a plan
10,019
$60.30K
1.8%
ANTX
AN2 Therapeutics, Inc.
3 Sep 2026
Director
Sold on a plan
6,100
$37.03K
1.1%
ANTX
AN2 Therapeutics, Inc.
17 Aug 2026
Director
Sold on a plan
35,402
$212.70K
5.9%
ANTX
AN2 Therapeutics, Inc.
10 Dec 2024
Director
Bought
10,000
$14.93K
1.6%
ANTX
AN2 Therapeutics, Inc.
9 Dec 2024
Director
Bought
30,772
$43.98K
5.0%
ANTX
AN2 Therapeutics, Inc.
6 Dec 2024
Director
Bought
19,228
$27.79K
3.2%
ANTX
AN2 Therapeutics, Inc.
27 Nov 2024
Director
Bought
50,000
$70.84K
8.7%
ANTX
AN2 Therapeutics, Inc.
26 Nov 2024
Director
Bought
25,000
$34.85K
4.4%
ANTX
AN2 Therapeutics, Inc.
20 Nov 2024
Director
Bought
50,000
$57.87K
9.3%
ANTX
AN2 Therapeutics, Inc.
19 Nov 2024
Director
Bought
150,000
$155.26K
36.6%
ANTX
AN2 Therapeutics, Inc.
12 Jan 2024
Director
Sold on a plan
1,425
$31.23K
0.3%
ANTX
AN2 Therapeutics, Inc.
10 Jan 2024
Director
Sold on a plan
3,669
$80.44K
0.9%
ANTX
AN2 Therapeutics, Inc.
29 Mar 2022
Director
Bought
153,334
$2.30M
45.9%
14 decisions on file.
